AllergoOncology: Generating a canine anticancer IgE against the epidermal growth factor receptor - 06/09/18
![](/templates/common/images/mail.png)
This work was supported by the Austrian Science Fund (FWF) grants P23398-B11, W1205-B09, and SFB F4606-B28. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' National Health Service Foundation Trust and King's College London (grant no. IS-BRC-1215-20006). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. The authors acknowledge support by Breast Cancer Now (147) working in partnership with Walk the Walk; the Medical Research Council (grant no. MR/L023091/1); Cancer Research UK (grant nos. C30122/A11527 and C30122/A15774); and CR UK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre (grant no. C10355/A15587). |
|
Disclosure of potential conflict of interest: J. Fazekas-Singer, J. Singer, and E. Jensen-Jarolim are inventors of can225IgG, which is claimed by the University of Veterinary Medicine Vienna, Austria. E. Jensen-Jarolim is founder and shareholder of Biomedical International R+D GmbH and inventor on nonrelated patents in allergen immunotherapy, antitumor vaccines, and biomedical imaging. S. N. Karagiannis is founder and shareholder of IGEM Therapeutics Ltd and coinventor of a patent on IgE antibodies for cancer therapy. J. Singer is coinventor of a nonrelated allergen immunotherapy patent. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 142 - N° 3
P. 973 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?